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ABSTRACT Two different approaches were used to study the kinetics of the enzymatic reaction under heterogeneous
conditions to interpret the unusual nonlinear pharmacokinetics of mibefradil. Firstly, a detailed model based on the kinetic
differential equations is proposed to study the enzymatic reaction under spatial constraints and in vivo conditions. Secondly,
Monte Carlo simulations of the enzyme reaction in a two-dimensional square lattice, placing special emphasis on the input and
output of the substrate were applied to mimic in vivo conditions. Both the mathematical model and the Monte Carlo simulations
for the enzymatic reaction reproduced the classical Michaelis-Menten (MM) kinetics in homogeneous media and unusual
kinetics in fractal media. Based on these ﬁndings, a time-dependent version of the classic MM equation was developed for the
rate of change of the substrate concentration in disordered media and was successfully used to describe the experimental
plasma concentration-time data of mibefradil and derive estimates for the model parameters. The unusual nonlinear
pharmacokinetics of mibefradil originates from the heterogeneous conditions in the reaction space of the enzymatic reaction.
The modiﬁed MM equation can describe the pharmacokinetics of mibefradil as it is able to capture the heterogeneity of the
enzymatic reaction in disordered media.
INTRODUCTION
Michaelis-Menten (MM) kinetics is a basic enzyme kinetics
scheme (Michaelis and Menten, 1913), used extensively in
chemistry and biology for the study of enzymatic cataly-
sis as it is a relatively simple model from a mathematical
point of view. It is of central importance in the ﬁeld of
biotransformation of drugs and is the core of nonlinear
pharmacokinetics (Wagner, 1993). The foundation of MM
formalism relies on the mass-action law as applied to
enzymatic reactions. However, the application of the mass-
action law and the derivation of MM kinetics both assume
that the substrate-enzyme reaction takes place in a homoge-
neous medium, i.e., well-mixed, three-dimensional (3D)
space and dilute conditions. Although this assumption is
usually satisﬁed under in vitro conditions, the complexity of
biological media makes it questionable when MM kinetics is
considered under in vivo conditions. Indeed, various reports
indicate that cellular media are structurally heterogeneous
(Scalettar et al., 1991; Minton, 1993, 1998; Luby-Phelps
et al., 1987; Frauenfelder et al., 1999) and this has an impact
on the validity of Fick’s law of diffusion in living cells
(Agutter et al., 1995). The reason is (see Berry, 2002 and
references therein) that diffusion depends on the Euclidean
dimension d of the medium in which it occurs. For a medium
with d. 2, a diffusing molecule explores only a low fraction
of the accessible volume and thus it always escapes its initial
position (noncompact diffusion). For a medium with d , 2,
the molecule eventually returns to its initial position with
probability 1 (compact diffusion) and thus diffusion is not
a perfectly mixing process in low dimensions (Montroll and
Weiss, 1965). This has important consequences on the mean-
squared displacement of the molecule, which scales with time
as ÆR2æ} tn: The exponent n ¼ 1 denotes Fickian diffusion
whereas n , 1, observed in many low-dimensional media,
denotes anomalous diffusion. Nonclassic diffusion has been
observed in cellular media for water (Ko¨pf et al., 1996), and
ﬂuorescence probes (Schwille et al., 1999; Wachsmuth et al.,
2000). In general, many cellular reactions take place under
dimensionally restricted conditions, e.g., two-dimensional
(2D) membranes, quasi-one-dimensional tubes or other
disordered media. This type of reaction has been found to
exhibit noninteger kinetic orders in in vitro experimental
studies (Sadana, 2001; Ramakrishnan and Sadana, 2002) and
in simulation (Koo and Kopelman, 1991), rather than the
usual integer kinetic order derived from mass-action kinetics.
These noninteger kinetic orders are related to the fractal
dimension of the space in which the reaction occurs;
therefore, the nonconventional kinetics have been referred
to as ‘‘fractal kinetics’’ (Kopelman, 1988). Typically when
power-law behavior is observed, this is manifested in a log-
log plot with a straight line section. At short times the system
is still not equilibrated enough and as this regime is ampliﬁed
by the log-log plotting, a straight line is not observed. This
happens only when the system has the chance to reach some
sort of equilibrium and this usually happens at long times.
In this context, theoretical approaches (Lo´pez-Quintela
and Casado, 1989; Berry, 2002; Savageau, 1998) based on
fractal principles have been used to describe enzyme kinetics
in low-dimensional disordered media. One of these ap-
proaches (Lo´pez-Quintela and Casado, 1989) has been also
used to interpret experimental data of carrier-mediated
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transport (Macheras, 1995; Ogihara et al., 1998). It is
proposed that the liver is a fractal-like object. In fact
Javanaud (1989), using ultrasonic wave scattering, has
measured the fractal dimension of the liver as approximately
df  2 over a wavelength domain of 0.15–1.5 mm. Recently,
Fuite et al. (2002) proposed that the fractal structure of the
liver with attendant kinetic properties of drug elimination can
explain the unusual nonlinear pharmacokinetics of mibe-
fradil (Skerjanec et al., 1996; Welker, 1998). In this work we
study the effect of species segregation on the kinetics of the
enzyme reaction, ﬁrstly by using a microscopic pharmaco-
kinetic model, and secondly by carrying out Monte Carlo
(MC) simulations mimicking the intravenous (i.v.) and per os
(p.o.) administration of the substrate for an enzyme reaction
taking place in fractal media. The substrate proﬁles gen-
erated from both approaches were found to be in accord with
mibefradil experimental observations. Based on these ﬁnd-
ings we developed a modiﬁed MM equation incorporating
the time dependence in the Michaelian ‘‘constant,’’ and we
further used it to interpret the unusual nonlinear pharmaco-
kinetics of mibefradil (Fuite et al., 2002; Skerjanec et al.,
1996; Welker, 1998) at the macroscopic level. We would like
to emphasize that the models presented below represent only
one possible explanation for reactions occurring in disordered
media and they are certainly not the only possible approach.
METHODS
The MM model of enzyme kinetics consists of three elementary chemical
reactions:
E1 S%
k1
k1
C/
k2
E1P; (1)
where E, S, P, and C represent the enzyme, substrate, product, and enzyme-
substrate complex, respectively, and ki is the rate coefﬁcient associated with
the elementary step i.
Because, after an initial prestabilized period, the concentration of the
complex (C) in Eq. 1 remains practically constant, a quasistationary state
assumption is used for simpliﬁcation purposes (Wagner, 1993). This
simpliﬁcation allows the derivation of the classic MM Eq. 1:
v ¼ vmaxpS
KM1 pS
; (2)
where v and vmax refer to reaction and maximum reaction rate, respectively,
ps is the substrate concentration whereas the term KM represents the MM
constant that is related to the kinetic constants of the reaction scheme (Eq. 1)
as follows:
KM ¼ ðk21 k1Þ=k1:
Mathematical formulation of a microscopic
reaction model of MM kinetics under
in vivo conditions
To model the above reaction scheme (Eq. 1) under in vivo conditions we
have to take into account that the substrate (drug) is not conﬁned at the
reaction medium (liver), but it arrives at the liver either from the portal vein
(oral administration) or through circulation (intravenous administration);
a part of the substrate is metabolized (Fig. 1) while the rest exits from the
liver and returns later through circulation, and so on.
We propose a reaction model that incorporates this fact, without,
however, dealing in detail with the drug partition between the blood and the
liver, by making the assumption that the substrate molecules that exit from
the liver at time t will return to it some time later. We also assume that this
time of delay is not constant, but it follows a Gaussian distribution with
mean T and variance s2. We further assume that E and C remain inside the
liver and that only P and S get out and return through the circulatory system.
Thus, the mathematical model for the in vivo MM reaction takes the form:
dpC
dt
¼ dpE
dt
¼ k1pEpS  ðk11 k2ÞpC (3)
dpS
dt
¼ k1pEpS1 k1pC1RSextðtÞ
 a1 pS1
Z u¼t
u¼0
a2 pS ðuÞe
ððtðu1TÞÞ2
2s
2ﬃﬃﬃﬃﬃﬃ
2p
p
s
du (4)
dpP
dt
¼ k2pC  a1 pp1
Z u¼t
u¼0
a3 pp ðuÞe
ððtðu1TÞÞ2
2s
2ﬃﬃﬃﬃﬃﬃ
2p
p
s
du; (5)
where pi is the concentration of species i at time t. Eqs. 4 and 5 represent
modiﬁcations of the classic system of ordinary differential equations used to
describe the MM scheme. The extra terms that have been added in Eqs. 4 and
5 are listed below along with their physical meaning:
1. RSext(t) in Eq. 4 is the arrival rate of S to the liver from the
gastrointestinal tract. It depends on the way the drug enters the
circulatory system at the liver area, and may have the following forms:
i.v. bolus injection: RSext(t) ¼ 0 and the system of Eqs. 3–5 has to
be solved with the initial condition ps(t ¼ 0) ¼ S0 . 0.
Zero-order input: RSext(t) ¼ k0 for t # Ta and 0 for t . Ta, where k0
is a constant and Ta is the duration of input from the
gastrointestinal (GI) tract. The system of Eqs. 3–5 has to be
solved with the initial condition ps(t ¼ 0) ¼ 0.
First-order input: RSext(t) ¼ ka 3 X0 3 ekat where X0 is a constant
quantity (initial concentration of drug in the GI) and ka is the
ﬁrst-order rate constant. Again the system of Eqs. 3–5 has to be
solved with the initial condition ps(t ¼ 0) ¼ 0.
FIGURE 1 A microscopic model for the enzymatic reaction in the liver.
The topology of the reaction space in the liver can be considered either
Euclidean or fractal. RSext denotes the rate of substrate input.
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2. a1 pS in Eq. 4 is the rate of exit of drug molecules.
3.
R u¼t
u¼0 a2 pS ðuÞðeððtðu1TÞÞ
2=2s2Þ=
ﬃﬃﬃﬃﬃﬃ
2p
p
sÞdu in Eq. 4 models the re-
entrance of drug due to the circulation. The term a2pSðuÞis the number
of drug molecules that exit at time u and the other term is the probability
that a drug molecule that exits at u will return at the liver at time t. We
integrate to account for the contribution from all times 0 , u , t.
4. a1 pp in Eq. 5 is the rate of exit of product molecules.
5.
R u¼t
u¼0 a3 pp ðuÞðeððtðu1TÞÞ
2=2s2Þ=
ﬃﬃﬃﬃﬃﬃ
2p
p
sÞdu in Eq. 5 models the re-
entrance of product due to the circulation.
The above system of integro-differential equations becomes even more
complicated as we have to take into consideration segregation effects that
will arise if we consider some degree of disorder in the medium. The basic
fractal kinetics assumption, which is supported by Monte Carlo simulations
(Kopelman, 1988; Berry, 2002; Kosmidis et al., 2003b), is that segregation
effects arising due to the fractal structure (in this case, the liver) can be
incorporated in the model if we assume that k1, a1,and a2 are not constant but
follow a power law. Thus, in the above model:
k1/
k1
tb
; a1/
a1
t
m; a2/
a2
t
m: (6)
In all results presented below, we have, for simplicity, assumed that a3¼
0, i.e., that the product molecules that exit the liver area do not return to
it. Because the quantity we are primarily interested in is the blood
concentration ps of substrate in the liver region this will not change the
results of the numerical solutions. It may, however, make a difference in the
Monte Carlo simulation results for ps at long times.
Monte Carlo simulations of enzyme reaction in
fractal media
We simulated the Michaelis-Menten reaction depicted in Eq. 1 using a 2D
square lattice and the Monte Carlo algorithm described below. See Fig. 2 for
a graph of a 50 3 50 percolation fractal. Each molecule type performs
a random walk on the lattice with excluded volume interactions. To model
the complexity of the environment we have two choices, both of them very
well known from percolation theory. Either we simply introduce immobile
obstacles at a given concentration, cb, and force particles to move anywhere
on the lattice but not on the obstacle sites, or we ﬁrst introduce immobile
obstacles at a given concentration cb and then we use a cluster labeling
technique (as, e.g., the one proposed by Hoshen and Kopelman (1976)) to
identify the largest cluster and allow the reaction to occur only at the largest
cluster. The largest cluster at the percolation threshold is known as the
percolation fractal. Below we will refer to the ﬁrst model as the ‘‘all-clusters
model’’ and to the second as the ‘‘largest-cluster model.’’ Both models will
produce statistically the same results at low concentrations of obstacles, but
will differ at long times if the concentration of obstacles is high and the
enzyme concentration is low. The reason is that every site of the ‘‘largest
cluster’’ is connected to every other site, whereas in the ‘‘all-clusters model’’
there are also several smaller ‘‘islands,’’ where there may be some substrate
molecules but no enzyme molecules can access them. Of course these small
‘‘islands’’ may be interpreted as areas where the MM reaction is more
difﬁcult to occur and both models may lead to useful results. Obviously,
when no obstacles are used, then the matrix represents a Euclidean space
with dimensionality equal to two. It should be noted that the ‘‘largest-cluster
model’’ has been used in the past in problems related to drug release from
polymeric devices (Bonny and Leuenberger, 1991, 1993; Kosmidis et al.,
2003a,b). The ‘‘all-clusters model’’ on the other hand was recently used by
Berry (2002) for simulating enzyme reactions in restricted geometries.
Although the liver is a 3D organ we utilize here a 2D model. This is
mainly due to simplicity, especially because both a 2D and a 3D percolation
cluster at criticality have the same spectral dimension. This exponent ds
characterizes the area visited by a random walker in a medium. A 2D lattice
has ds ¼ 2, whereas a disordered lattice (percolation fractal) has a spectral
dimension ds; 1.34, both in 2D and 3D lattices (Argyrakis et al., 1993). By
inserting immobile obstacles in a 2D lattice and varying their concentration
we are able to control the spectral dimension of the medium in a continuous
way from 2 to 1.34. The value of the spectral dimension of the liver given by
Fuite et al. (2002) is ds ; 1.84, which is within the above interval (1.34–
2.50) and in agreement with our proposed picture. Actually, it was possible
to ﬁt the same experimental data as Fuite with our 2D model and produce
a better more accurate ﬁt. Thus, using a 2Dmodel per se, is not misleading or
questionable.
To mimic the enzyme reaction under in vivo conditions, special emphasis
is given to the input and output of the substrate and the output of the product.
To this end, we introduce sites that function as exits with a concentration cout
and sites that function as entrances with a concentration cin, (see Fig. 2). In all
cases presented below (unless otherwise denoted) we have used a 1003 100
lattice with cin ¼ 0.3 and cout ¼ 0.1.
Reaction-diffusion processes are usually simulated using a random-walk
model. To model a Michaelis-Menten type of reaction, which is actually a set
of three elementary reactions (see Eq. 1) we have to introduce three reaction
probabilities f, r, and g. These probabilities are proportional to the rate
coefﬁcients k1, k1, and k2 (see below and also Berry, 2002). To mimic i.v.
bolus injection-type delivery of the drug, at the beginning of each
simulation, the E and S molecules are randomly placed on the permissible
clusters of the lattice.
To mimic ﬁrst-order drug delivery we calculate the number of substrate
molecules Next that enter the liver, through the GI tract, from time t until
t 1 1 using the relation Next ðtÞ ¼
R t11
t
ka X0 Expðka tÞ dt; where X0 is the
initial quantity of drug in the GI and ka is the ﬁrst-order rate constant. In
simulations using the ‘‘largest-cluster’’ model we set the substrate
concentration cs at a constant value and we set X0 ¼ cs lf, where lf is the
size of the percolation fractal. (For a 1003 100 lattice the average size of the
percolation fractal is a little more than 2500 sites). Those X0 molecules are
gradually placed at the percolation fractal. At each MCS we place Next
substrate molecules around the sites labeled as entrances.
At each MC step, an occupied lattice site is chosen at random (excluding
obstacle sites). The rules for movement and reaction depend on the nature of
the selected molecule:
1. If the selected molecule is an S, a destination site is chosen at random
from its four nearest neighbors. If the destination site is unoccupied, the
molecule moves to it directly. If the destination site is occupied by an E
molecule, a random number is chosen between 0 and 1. If this number is
lower than the reaction probability f, the destination site is turned to a C
FIGURE 2 A 50 3 50 percolation fractal. Only the largest cluster is
shown. Particles are allowed to move on the white sites only. Black sites are
restricted area obstacles. Substrate molecules enter to the lattice from
randomly chosen white sites labeled as entrances.
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molecule and the initial S site becomes unoccupied. In all other cases,
the S molecule remains at its initial position. Note that this is also valid
if the chosen destination site is an obstacle.
2. If the selected molecule is an E, the process is similar to case 1, i.e.,
depends on the occupancy status of the randomly chosen destination
site. There is a movement if unoccupied, whereas there is a reaction
with a probability f if occupied by S, or there is no change in all other
cases.
3. If the selected molecule is a C, a random number is chosen between
0 and 1. If this number is lower than the reaction probability r then the C
molecule dissociates into an E and an S. The new E molecule is placed
on the initial C site, whereas for the new S molecule we choose a site at
random. If the site is occupied we abort the decomposition process. The
initial C molecule dissociates into an E and a P in a similar fashion, if
the random number is .r but lower than r 1 g. Finally, if the random
number is greater than r 1 g, the C molecule is allowed to move to
a randomly chosen unoccupied nearest neighbor site.
4. If the chosen molecule is a P, it moves to a randomly chosen
unoccupied nearest-neighbor site.
5. Sites marked as exits function as block sites for E and C molecules. This
accounts for the fact that the enzyme and substrate molecules are not
allowed to exit from the liver area. On the other hand a P molecule that
meets an exit site is permanently removed from the system.
6. If an S molecule moves to an exit site at time t, a random number x is
drawn from a Gaussian distribution with mean t and standard deviation
s. This particle will return to the system at time t 1 x and it will be
placed at a randomly chosen nearest neighbor of an entrance site.
After each particle move time is incremented by 1/N, where N is the
current number of molecules on the lattice. One time unit thus statistically
represents the time necessary for each molecule to move once. The
simulation goes on until a prescribed total time is reached. We average our
results over 50 realizations for statistical purposes.
RESULTS AND DISCUSSION
Microscopic modeling and MC Simulations
In Fig. 3 we present a plot of pS versus time based on the
numerical solution of the microscopic reaction model and
subsequent ﬁtting to the experimental in vivo data (also
shown in the plot) using a Levenberg-Marquardt nonlinear
ﬁtting algorithm (Press et al., 1988). The ﬁtted line describes
the experimental data nicely. Notice the hump around t ¼ 50
min, which is predicted from the model and also observed
experimentally. It is due to the fact that the drug molecules
that exit from the liver return to it after some time, thus
temporally increasing ps, which subsequently is decreased
again due to the continuous exiting of substrate particles
from the system. The estimates of the parameters (in
arbitrary units) of the system of Eqs. 3–6 are: ps(0) ¼ 0.3,
pe(0) ¼ 0.05, k1 ¼ 1, k1 ¼ 0.02, k2 ¼ 0.09, a1 ¼ 0.0302,
a2 ¼ 0.0305, t ¼ 48, s ¼ 10, b ¼ 0.39, m ¼ 0.07. The
correspondence of arbitrary time and density units to the
actual units is also determined by the Levenberg-Marquardt
and it is found that 1 arbitrary density unit corresponds to
477.99 ng/mL and that 1 arbitrary time unit corresponds to
1.07 min. Particular emphasis should be placed on the
estimate b ¼ 0.39 for the power-law exponent of
‘‘segregation’’ term k1/t
b (in Eq. 6) because it indicates
a reaction taking place at a highly disordered environment.
This result is in good agreement with the results of Berry
(2002) who also found that k1 is in essence a time-dependent
coefﬁcient in topologically constrained media. It is also
interesting to note that the estimate for m was found to be
close to zero (m ¼ 0.07), which indicates that both the exit
and reentrance of the drug are governed by typical rate
constants a1 and a2 ; respectively, Eq. 6.
To check the validity of the MC simulations in Fig. 4 we
plot pS versus time for several different enzyme con-
centrations (pE) assuming that no obstacles are present,
which is a case of normal Euclidean space. We assume i.v.
bolus injection delivery of the drug. So all drug molecules
are placed at the 2D matrix at random positions at time t¼ 0.
The values assumed for the reaction probabilities are f ¼ 1,
r ¼ 0.02 and g ¼ 0.04, and ps(0) ¼ 0.2. The results indi-
cate that the substrate concentration decreases exponentially
at long times, which is the classically expected behavior
anticipated from the Michaelis-Menten reaction scheme in
saturated conditions (Wagner, 1993). The condition for this
exponential decrease is Km  ps, i.e., when the substrate
concentration becomes much less than the Michaelis
constant (Murray, 1993).
Fig. 5 is a semilog plot of the Monte Carlo simulation data
for pS versus time assuming delivery of the drug through
ﬁrst-order kinetics. We have assumed a fractal structure
using the largest-cluster model. The values assumed for the
reaction probabilities are f ¼ 1, r ¼ 0.02, and g ¼ 0.04 and
the initial enzyme concentration was set to pe ¼ 0.06. All
lines represent simulation results. Notice the reaction
FIGURE 3 Plot of pS versus time using the microscopic model of the
enzymatic reaction. Points are experimental in vivo data from Fuite et al.
(2002). The solid line represents results of the numerical solution of the
system of Eqs. 3–5 assuming fractal kinetics (i.e., Eq. 6) combined with
a Levenberg-Marquardt ﬁtting algorithm. The ﬁtted results are rescaled to
change to actual units. Rescaling factors are also determined by Levenberg-
Marquardt ﬁtting.
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slowdown (slope change) at large times in contrast to the
classical behavior presented in Fig. 4. This can be interpreted
as an indication of ‘‘fractal’’ instead of classical kinetics.
High values of the ﬁrst-order rate constant ka approximate
injection delivery whereas low values of ka mimic slow oral
drug input. Experimental results (see also discussion of Fig.
7) show that a high ka value exhibits a deviation from the
classically expected Michaelis Menten behavior, but this is
not observed in the oral administration of drug. Simulation
results shown in Fig. 5 indicate that high ka values lead to
higher initial drug concentration and to ‘‘fractal kinetics’’
(Berry, 2002) behavior whereas this effect is not so obvious
for low ka values. In fact, fractal kinetics is completely
masked for the simulations with low initial substrate
concentration and low value of ka.
In all Monte Carlo simulations that monitor the time
evolution of a system the time unit of the simulation is 1
Monte Carlo step (MCS). The correspondence of this time
unit to the actual time units used in the experimental
measurements is determined by a nonlinear ﬁtting and is
found that 1 MCS corresponds to 0.88 min.
In Fig. 6 we present a plot of pS versus time based on the
Monte Carlo method. Points are the experimental in vivo
data from Fuite et al. (2002), same as in Fig. 3. The dashed
line is the MC simulation result using the ‘‘all-clusters
model’’ and the solid line is the MC result using the ‘‘largest-
cluster model.’’ We performed several simulations under
different conditions. In all cases, to achieve the best possible
ﬁtting, we had to assume a fractal structure for the liver either
by assuming a concentration of obstacles near the percola-
tion threshold in Monte Carlo simulations or by assuming
a power-law form for the ‘‘constants’’ as in Eq. 6 in the
mathematical modeling. Visual inspection of Fig. 6 reveals
that the MC results derived from the ‘‘all-clusters model’’
describe better the experimental data than the ‘‘largest-
cluster model.’’ Any attempt to explain the experimental
results using the classical Michaelis-Menten was completely
unsatisfactory.
Development and application of an MM equation
with time-variant Km
In addition to the detailed mathematical model that we have
presented above, we would like to provide a simpler,
approximate, treatment of the problem, which is much easier
to use in practical applications.
An algebraic manipulation of the system of Eq. 3–6, using
the classical quasistationary assumption and the additional
assumptions that a1, a2 are small compared to k1 and that in
most cases RSext(0) is also small, implies that a time-variant
KM will be a suitable approximation. In fact, the above
analysis indicates that a power-law form is probably the most
appropriate for the time-variant KM as follows: KM ¼ KM0 
th, where h is a dimensionless exponent and KM0 is a constant
expressed in concentration (time)h units. Under homoge-
neous conditions, the terms KM and KM0 become identical
and express the classic Michaelis constant since h¼ 0. Using
the time-variant expression of KM, the time-dependent
version of MM kinetics can be formulated as:
FIGURE 4 Semilog plot of pS versus time for several initial values of
enzyme concentration, pE, in a Euclidean space (zero density of obstacles)
using MC simulation. We assume injection-type drug delivery, i.e., at t ¼
0 all drug molecules are supposed to be in the lattice, randomly distributed.
The values assumed for the reaction probabilities are f¼ 1, r¼ 0.02, and g¼
0.04. The initial substrate concentration was set to ps ¼ 0.2.
FIGURE 5 MC simulations using the ‘‘largest-cluster model’’. Semilog
plot of pS versus time assuming delivery of the drug through ﬁrst-order
kinetics for several values of the ﬁrst-order constant, ka, and two levels of
the initial substrate concentration. The values assumed for the reaction
probabilities are f ¼ 1, r ¼ 0.02, and g ¼ 0.04 and the initial enzyme
concentration is pe ¼ 0.06.
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v ¼ vmaxpS
KM0t
h1 pS
: (7)
Equation 7 reveals that the rate of the enzyme reac-
tion depends on ps and t. This time dependency of KM (KM¼
KM03 t
h) leads to an increase of this term with time (depend-
ing also on the value of the exponent, h). This character-
istic constitutes the underlying cause for the successful
application of Eq. 7 to mibefradil data.
Assuming one-compartment model disposition (Wagner,
1993), Eq. 7 was used to analyze the concentration-time data
of mibefradil after i.v. and per os administration (Fuite et al.,
2002; Skerjanec et al., 1996; Welker, 1998). For comparative
purposes the classic Eq. 2 was also used to analyze the same
data. Since Eqs. 2 and 7 were applied to concentration-time
data (Fuite et al., 2002), the term vmax was substituted with
v*max denoting the normalized maximum rate, in terms of the
volume of distribution of the compartment. These appropri-
ately modiﬁed Eqs. 2 and 7 were ﬁtted to experimental data
(Fuite et al., 2002; Skerjanec et al., 1996; Welker, 1998)
using a program developed in FORTRAN for the numerical
solution of the differential equations. A Levenberg-Mar-
quardt algorithm was utilized for the optimization process.
To compare the utilized models as for their ability to
successfully describe the data, the Akaike information
criterion (AIC), and the Schwarz information criterion
(SIC) were used (Gabrielsson and Weiner, 1997).
Fig. 7 A shows a semilogarithmic plot of the results
derived from the ﬁtting of Eq. 7 to the ﬁrst set of human
bolus intravenous data (Fuite et al., 2002). The inset in Fig.7
A represents the ﬁtting results of Eq. 2 to the same data. The
values of the optimized parameters are quoted in Table 1.
Visual inspection of Fig. 7 A and its inset reveals that Eq. 7
can successfully describe these data, whereas this is not
the case for the classic MM approach (Eq. 2). The same
conclusions can be derived from the analysis of the second
set of intravenous data (Skerjanec et al., 1996), which are
shown in Fig.7 B (for Eq. 7) and at the inset of Fig.7 B for
Eq. 2. Again, Eq. 7 shows a very good description of the
experimental data, whereas the classic MM model fails to
describe the data adequately. The parameter estimates for the
second set of intravenous data derived after optimization
along with the statistical criteria values are listed in Table 1.
It should also be noted that these observations agree with the
values of the corresponding statistical criteria (AIC, SIC)
(see Table 1).
The analytical power of Eqs. 2 and 7 was also tested using
mibefradil data obtained after oral administration (Skerjanec
et al., 1996; Welker, 1998). To this end, the ﬁtting of Eqs. 2
and 7 was applied only to the data of the declining limb of the
concentration-time curve. For both oral data sets examined,
the two models described the data correctly (results are not
FIGURE 6 Plot of pS versus time. Points are experimental in vivo data
from Fuite et al. (2002). Dashed line represents MCS results using the ‘‘all-
clusters model’’. The values assumed for the reaction probabilities are f¼ 1,
r ¼ 0.02, and g ¼ 0.04. The following parameters have given the best ﬁtting
results: ps(0) ¼ 0.2, pe(0) ¼ 0.2, T ¼ 48, s ¼ 12. Thin solid line represents
MCS results using the ‘‘largest-cluster model’’. The following parameters
have given the best ﬁtting results: f ¼ 1, r ¼ 0.015, g ¼ 0.02, ps(0) ¼ 0.6,
pe(0)¼ 0.2, T¼ 48, s¼ 10. We rescale to change fromMonte Carlo units to
actual time units. Rescaling factors are determined by Levenberg-Marquardt
ﬁtting. In both cases it turns out that 1 min ¼ 0.88 MC steps.
FIGURE 7 Semilogarithmic concentration (ps) versus time plots of
mibefradil after intravenous bolus administration. Data were taken from
reference Fuite et al. (2002) (A), and reference Skerjanec et al. (1996) (B).
The solid lines represent the ﬁttings of Eqs. 2 (A and B insets) and 7 (A and
B) to experimental data.
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shown). The estimates of the model parameters and the
values of the statistical criteria for the oral data ﬁttings are
listed in Table 1 under the two columns with the p.o. sign.
The discrepancy of the ﬁtting results between the
intravenous and oral data is associated with the speciﬁc
kinetic characteristics of the two types of administration.
After intravenous bolus administration the entire quantity of
drug reaches the liver as a ‘‘bolus’’ through the hepatic
artery. On the contrary, the drug (substrate) reaches the liver
gradually via the portal vein following the rate of uptake
after oral administration. Besides, mibefradil exhibits
extensive ﬁrst-pass effect and therefore the portal vein
concentration of the gradually absorbed mibefradil is
considerably lower than the plasma concentrations of
intravenous bolus administration. All these observations
substantiate the view that only the i.v. bolus administration
creates favorable conditions for the manifestation of fractal
kinetics characteristics of the enzyme reaction.
To further verify our physically based interpretation for
the differences noted in the analysis of i.v. and oral
experimental data, a pharmacokinetic simulation study was
undertaken. A model with one-compartment disposition,
ﬁrst-order input and elimination following Eq. 7 was
utilized. Two sets of oral data were generated utilizing a high
value for the absorption rate constant, ka¼ 1.0 (arbitrary time
units)1 to mimic a rapid ‘‘intravenous-like’’ drug admin-
istration and a low value for ka ¼ 0.01 (arbitrary time
units)1 implementing a slower input rate. Again, Eqs. 2 and
7 were utilized for the analysis of the declining phase data.
The ﬁtting results obtained from the simulation data, Fig. 8,
were found to be in agreement with the results of the
experimental data. The time-dependent MM model (Eq. 7)
described nicely both the two sets of data (Fig. 8, A and B). In
contrast, Eq. 2 described the data correctly when a low value
was assigned to the absorption rate constant (Fig. 8 B inset)
and failed to describe the data adhering to the higher input
rate (Fig. 8 A inset).
A decrease in metabolic clearance with time for certain
drugs is usually attributed to self-inhibition (Wolf et al.,
1997). However, the manifestation of self-inhibition requires
repetitive administration of the drug inhibiting its own
metabolism. In this study, the mechanism that caused the
time dependency of KM for mibefradil was attributed to
spatial restriction of the in vivo reactions because the
reduction in clearance was observed during the time course
of a single i.v. bolus administration. To the best of our
knowledge, this is the ﬁrst physically based mechanism
proposed for the reduction in metabolic clearance with time.
However, a singular observation for the increase of
Michaelis constant (KM) of cyclosporine during the ﬁrst
four months after transplantation (Wolf et al., 1997) has not
been elucidated as yet. This mechanism could be proposed,
because both the simulation (Berry, 2002) and the
experimental results quoted above indicate that the ‘‘time-
scale’’ for the manifestation of KM reduction depends on the
‘‘reaction conditions’’ (substrate (drug), enzyme, substrate
density (dose), route of administration, input rate). In
parallel, one should also add that cyclosporine causes
hepatic toxicity leading to histological changes that can
progressively affect the topological constraints of the
reaction space because in vivo reactions occur on mem-
branes or channels of the hepatic cells (Savageau, 1998). It
was shown above that the microscopic model and the Monte-
Carlo simulations for the enzyme reaction taking place in
TABLE 1 Parameter values derived after optimization of two models using experimental and simulated data
Data set* (route, reference)
Parameter
i.v.
(Fuite et al., 2002)
i.v. (Skerjanec
et al., 1996)
p.o. (Skerjanec
et al., 1996)
p.o. (Welker,
1998) sim1y sim2z
Eq. 2
v*max (ng/mL/min) 6791.4 (48,366.7) 467.9 (1098.2) 1.03 (0.3) 19.9 (2.9) 222.7 (169.5) 157.1 (10.3)
KM (ng/mL) 70,215.0 (499,008.0) 12404.9 (29,369.9) 506.4 (172.9) 10,819.6 (1678.7) 36,052.5 (26,024.0) 61,166.2 (32,94.9)
AIC§ 97.2 112.1 36.4 30.8 73.0 23.3
SIC{ 97.8 112.7 35.7 30.4 73.8 24.1
Eq. 7
v*max (ng/mL/min) 71.9 (6.5) 88.4 (6.8) 0.824 (0.04) 0.269 (0.05) 1.168 (0.05) 1.029 (0.09)
KM0 (ng/mL 3 (min)
h) 154.8 (18.4) 273.4 (38.8) 50.3 (9.1) 2.59 (1.8) 4.681 (0.37) 272.02 (28.8)
h 1.0 (0.0) 0.84 (0.02) 0.325 (0.02) 0.595 (0.04) 0.760 (0.007) 0.0636 (0.03)
AIC§ 71.9 83.0 30.9 30.0 33.7 28.9
SIC{ 72.8 83.9 29.7 29.4 34.9 30.1
Values of the statistical criteria applied to the optimization results of the two models.
*The value in parentheses represents standard deviation.
ySimulated data were generated using ka ¼ 1.0 (arbitrary time units)1 to mimic a rapid ‘‘intravenous-like’’ drug administration; estimates for v*max, KM, and
Km0 are in arbitrary units.
zSimulated data were generated using ka ¼ 0.01 (arbitrary time units)1 to mimic oral drug administration; estimates for v*max, KM, and Km0 are in arbitrary
units.
§Akaike information criterion (Gabrielsson and Weiner, 1997).
{Schwarz information criterion (Gabrielsson and Weiner, 1997).
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a disordered medium can explain the unusual nonlinear
pharmacokinetics of mibefradil. These ﬁndings allow one
to infer that fractal kinetics governs the biotransformation
of mibefradil at the microscopic level and this is actually
observed at the macroscopic level. Based on the above we
propose a novel pharmacokinetic model that provides a more
realistic approach than the conventional MM formalism,
and it is much simpler to implement than the complete
mathematical treatment of Eqs. 3–6. We emphasize once
more that the macroscopic model described by Eq. 7 is not
supposed to represent the unique approach for the de-
scription of anomalous MM kinetics. However, Eq. 7 was
not derived empirically but it was based on our MC
simulations.
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